
Assembly Biosciences (ASMB) Stock Forecast & Price Target
Assembly Biosciences (ASMB) Analyst Ratings
Bulls say
Assembly Biosciences Inc. is advancing its hepatitis B virus (HBV) cure program, which has the potential to significantly improve the current low cure rates through the development of novel small molecule therapeutics aimed at multiple steps of the HBV lifecycle. The company's progress includes promising clinical data supporting the robustness of its drug candidates, including ABI-5366, which has demonstrated substantial antiviral activity and the possibility for future lifecycle expansion. Furthermore, a recent $175 million equity financing is expected to fund Assembly Biosciences through 2027, underpinning its optimistic financial outlook and potential for substantial revenue generation from its innovative HBV therapies.
Bears say
Assembly Biosciences Inc. is facing significant challenges in advancing its HBV-cure program, as negative outcomes from its clinical trials, particularly for the ABI-6250 and ABI-1179/5366 candidates, raise concerns about their future in the clinic. The company's financial health is further undermined by a persistent history of losses, emphasizing the lack of a proven track record of profitability. Additionally, adverse safety signals, poor efficacy results, and limited virologic responses in clinical trial participants may hinder investor confidence and impact future revenue generation.
This aggregate rating is based on analysts' research of Assembly Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Assembly Biosciences (ASMB) Analyst Forecast & Price Prediction
Start investing in Assembly Biosciences (ASMB)
Order type
Buy in
Order amount
Est. shares
0 shares